NCT00268346View on ClinicalTrials.gov

Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

January 31, 2011

Study Completion Date

August 31, 2011

Conditions
Esophageal Cancer
Interventions
DRUG

ZD1839

ZD1839 treatment will be taken once a day PO, every day about the same time

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00268346 - Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer | Biotech Hunter | Biotech Hunter